Product Name: JAK3Selectide
Product Number: PE-01BHS95
Size: 200 µg      Price:52.00
1 mg      $US104.00
5 mg      227.00
Peptide Name: JAK3Selectide

Product Use: For assaying the phosphotransferase activity of Janus protein-tyrosine kinase 3 (UniProt ID P52333).

Peptide Production Method: Solid-phase peptide synthesis

Peptide Sequence: KKGLEDDDYVNVFG

Peptide Modifications N Terminus: Free amino

Peptide Modifications C Terminus: βAla-Cys

Peptide Molecular Mass Calculated: 1772.88 Da

Peptide Purity Percent after Synthesis and Purification: >95

Peptide Appearance: White powder

Peptide Form: Solid

Storage Conditions: -20°C

Peptide Recommended Enzyme: JAK3

Scientific Background: JAK3 is a protein-tyrosine kinase of the TK group and JakA family. Phosphorylation at T8, Y904 and Y980 increases phosphotransferase activity. Phosphorylation at Y939 also increases phosphotransferase activity and induces interaction with STAT5A. Phosphorylation at Y785 induces interaction with SH2-B-beta. Phosphorylation at Y981 inhibits phosphotransferase activity. It is involved in cytokine receptor-mediated intracellular signal transduction, including activation of an oncoprotein, PI3K. JAK3 may be an oncoprotein (OP). JAK3 mutations were commonly found in juvenile myelomonocytic leukemia from whole-exome sequencing studies from 13 individuals. JAK3 were hypothesized to be involved in the progression rather than the initiation of leukemia, and patients with mutated JAK3 were associated with poorer clinical results. Mutations in this gene have been found in blood, mouth, and ovarian cancers.